Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial

Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing chronic lymphocytic leukemia (CLL). Minimal residual disease (MRD) assessment at 12 months (M12) post-HSCT is predictive of relapse. This phase II study aimed to achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Tournilhac, Olivier, Le Garff-Tavernier, Magali, Quoc, Stéphanie Nguyen, Forcade, Edouard, Chevallier, Patrice, Legrand-Izadifar, Faezeh, Damaj, Gandhi Laurent, Michonneau, David, Tomowiak, Cécile, Borel, Cécile, Orvain, Corentin, Turlure, Pascal, Redjou, Rabah, Guillerm, Gaëlle, Vincent, Laure, Simand, Celestine, Lemal, Richard, Quiney, Claire, Combes, Patricia, Pereira, Bruno, Calvet, Laure, Cabrespine, Aurélie, Bay, Jacques-Olivier, Leblond, Véronique, Dhédin, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252930/
https://www.ncbi.nlm.nih.gov/pubmed/32527951
http://dx.doi.org/10.3324/haematol.2019.239566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252930/
https://www.ncbi.nlm.nih.gov/pubmed/32527951
http://dx.doi.org/10.3324/haematol.2019.239566

Ejemplares similares